Tempol
- Generic Name
- Tempol
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C9H18NO2
- CAS Number
- 2226-96-2
- Unique Ingredient Identifier
- U78ZX2F65X
- Background
Tempol has been used in trials studying the treatment of Anal Cancer.
- Associated Conditions
- -
- Associated Therapies
- -
Effects of an Antioxidant Supplement on Blood Vessel Health
- Conditions
- Interventions
- First Posted Date
- 2024-05-22
- Last Posted Date
- 2024-12-09
- Lead Sponsor
- University of Georgia
- Target Recruit Count
- 60
- Registration Number
- NCT06424756
- Locations
- ๐บ๐ธ
Ramsey Student Center, University of Georgia, Athens, Georgia, United States
Treatment of Metastatic Cancer in Terminally Diagnosed Patients
- Conditions
- First Posted Date
- 2022-08-08
- Last Posted Date
- 2022-09-01
- Lead Sponsor
- Matrix Biomed, Inc.
- Registration Number
- NCT05491928
- Locations
- ๐บ๐ธ
UCHealth University of Colorado Cancer Center - Anschutz Medical Campus, Aurora, Colorado, United States
Study to Evaluate the Effects of Tempol (MBM-02) in COVID-19 Patients.
- First Posted Date
- 2021-01-28
- Last Posted Date
- 2022-12-06
- Lead Sponsor
- Adamis Pharmaceuticals Corporation
- Target Recruit Count
- 248
- Registration Number
- NCT04729595
- Locations
- ๐บ๐ธ
Sunrise Research Institute, Sunrise, Florida, United States
๐บ๐ธMonroe Biomedical Research, Monroe, North Carolina, United States
๐บ๐ธEastside Research Associates, Redmond, Washington, United States
The Effect of Antioxidants on Skin Blood Flow During Local Heating
- Conditions
- Interventions
- First Posted Date
- 2018-09-21
- Last Posted Date
- 2018-09-21
- Lead Sponsor
- The University of Texas at Arlington
- Target Recruit Count
- 44
- Registration Number
- NCT03680638
- Locations
- ๐บ๐ธ
Engineering Research Building, Arlington, Texas, United States
Treatment of Radiation and Cisplatin Induced Toxicities with Tempol
- Conditions
- Interventions
- First Posted Date
- 2018-03-29
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- Matrix Biomed, Inc.
- Target Recruit Count
- 120
- Registration Number
- NCT03480971
- Locations
- ๐บ๐ธ
University of Washington Medical Center, Seattle, Washington, United States
๐บ๐ธWake Forest University Health Sciences, Winston-Salem, North Carolina, United States
๐บ๐ธUCSD, La Jolla, California, United States
Topical MTS-01 for Dermatitis During Radiation and Chemotherapy for Anal Cancer
- Conditions
- Interventions
- First Posted Date
- 2011-03-28
- Last Posted Date
- 2021-11-23
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 6
- Registration Number
- NCT01324141
- Locations
- ๐บ๐ธ
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.